Sushil Patel Sells 10,000 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Replimune Group Stock Performance

REPL stock traded down $0.06 during midday trading on Wednesday, hitting $11.66. The company’s stock had a trading volume of 861,266 shares, compared to its average volume of 1,045,915. The stock has a market cap of $797.74 million, a price-to-earnings ratio of -3.82 and a beta of 1.26. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock’s 50-day moving average price is $12.22 and its 200 day moving average price is $10.62. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, equities analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its holdings in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Replimune Group in the second quarter valued at $57,000. Erste Asset Management GmbH purchased a new position in shares of Replimune Group during the 3rd quarter valued at $133,000. Arizona State Retirement System bought a new position in shares of Replimune Group during the 2nd quarter worth $108,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after acquiring an additional 5,926 shares during the period. 92.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

REPL has been the topic of several recent research reports. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. raised their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. BMO Capital Markets upped their price target on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Jefferies Financial Group raised their price objective on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Buy” and an average target price of $17.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.